NCI is developing a national Patient-Derived Models Repository (PDMR)
The National Cancer Institute (NCI) is building a national resource of cancer cell models derived from patients in NCI-sponsored clinical trials. This Patient-Derived Models Repository (PDMR) will contain patient-derived xenografts, primary and metastatic tumor cell cultures, blood specimens, cancer associated fibroblasts and organoids to boost public-private partnerships and academic drug discovery efforts. The tissue samples from SCLC, pancreatic, bladder, head and neck, sarcoma, Non-Hodgkin Lymphoma and melanoma will also be stored and made publically available upon request.
All the related information including smoking and therapeutic history, race/ethnicity, whole exome and RNA Sequence data about these preclinical models will be available to the intramural and extramural investigators, academia and pharmaceutical companies through an easily accessible database. This repository will augment reproducibility and transparency of preclinical data on drug efficacy and target identification, limit the use of animal models and will lead to more therapeutic success in the clinic.
Please, fill out a PDMR Model Request Form and Material Transfer Agreement (MTA) for standard research-use, but also submit a 2-page summary of the research plan if interested in collaboration. To check out related information, please click here. For further enquiries, please e-mail at: NCI_PDM_Repository@mail.nih.gov.